Yüksek genetik bariyerli antivirallerle tedavi edilen kronik hepatit B hastalarında gözlenen yan etkiler

Amaç: Bu çalışmada, kronik hepatit B (KHB) tedavisinde kullanılan entekavir ve tenofovirin kullanılması sırasında ortaya çıkan yan etkilerin belirlenmesi amaçlandı. Materyal ve Metot: Çalışmaya KHB tanısı alarak en az 6 aydır entekavir ya da tenofovir alan hastalar alındı. Hastaların dosya bilgileri retrospektif olarak değerlendirildi. Tümünde tedavi başlandıktan sonra ortaya çıkan yakınmalar, her kontroldeki fizik muayene ve laboratuar bulguları incelendi. Bulgular: Çalışma sonunda entekavir ile tedavi edilen 33, tenofovir ile tedavi edilen 26 hasta olduğu; entekavir ile tedavi edilen hastaların %60,6’sında, tenofovir ile tedavi edilenlerin ise %46,2’sinde hiç yan etki görülmediği tespit edildi. Her iki ilacı alan hastalarda da en sık görülen yan etki halsizlikti. Hiçbir hastada yan etki nedeni ile tedavi sonlandırılmamıştı. Sonuçlar: Entekavir ve tenofovir, ciddi düzeyde yan etkisi olmayan güvenli ilaçlar gibi görünmektedir.

The side effects of antivirals with high barrier to resistance in patients chronic hepatitis B

Aim: Entecavir and tenofovir are the first line therapeutic options in chronic hepatitis B (CHB) treatment. In this study we aimed to investigate the side effects of entecavir and tenofovir. Material and Methods: This was a clinical retrospective study. The patients with CHB who were treated with entecavir or tenofovir for at least 6 months were included in the study. The complaints which occured after the initiation of treatment, physical examination findings and laboratory results were investigated. Results: We found that there were 33 patients who received entecavir whereas 26 patients received tenofovir therapy. 60.6% of the entecavir-treated patients had no side effects while the ratio in the entecavir-treated patients was 46.2% The most frequent side effect was weakness in all patients. No entecavir or tenofovir treated patient discontinued therapy due to the adverse events. Conclusion: According to the results, entecavir and tenofovir were both safe without any serious side effects.

PDF

___

1. European Association for the Study of the Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-42.
2. Khungar V, Han SH. A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B. Curr Hepatitis Rep 2010;9:75-90.
3. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
4. Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010;3:107-19.
5. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. Am J Gastroenterol 2011; Mar 1: Epub ahead of print.
6. Yurdaydın C. Entecavir a step forward in combating hepatitis B disease. Expert Opin Pharmacother 2008;9:3095-109.
7. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological and mitochondiral abnormalities. Kidney Int 2010;78:1171-7.
8. Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother. 2008;52:598-605.
9. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
10. Durval A, Zamidei L, Bettocchi D, Luzzio MG, Consales G. Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir. Minerva Anestesiol 2011; Jan 18:Epub ahead of print.
11. Periard D, Yerly P, Hayoz D, Mazzolai L, Widmeier A, Cavassini M. Lower limb high arterial flow induced by tenofovir and emtricitabine treatment. Antivir Ther 2009;14:865-7.
12. Poordad F, Chee GM. Viral resistance in Hepatitis B: Prevalance and management. Curr Gastroenterol Rep 2010;12:62-9.
13. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-73.